These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
412 related articles for article (PubMed ID: 29429782)
21. Intracisternal cyclodextrin prevents cerebellar dysfunction and Purkinje cell death in feline Niemann-Pick type C1 disease. Vite CH; Bagel JH; Swain GP; Prociuk M; Sikora TU; Stein VM; O'Donnell P; Ruane T; Ward S; Crooks A; Li S; Mauldin E; Stellar S; De Meulder M; Kao ML; Ory DS; Davidson C; Vanier MT; Walkley SU Sci Transl Med; 2015 Feb; 7(276):276ra26. PubMed ID: 25717099 [TBL] [Abstract][Full Text] [Related]
22. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease. Camargo F; Erickson RP; Garver WS; Hossain GS; Carbone PN; Heidenreich RA; Blanchard J Life Sci; 2001 Nov; 70(2):131-42. PubMed ID: 11787939 [TBL] [Abstract][Full Text] [Related]
23. Collaborative development of 2-hydroxypropyl-β-cyclodextrin for the treatment of Niemann-Pick type C1 disease. Ottinger EA; Kao ML; Carrillo-Carrasco N; Yanjanin N; Shankar RK; Janssen M; Brewster M; Scott I; Xu X; Cradock J; Terse P; Dehdashti SJ; Marugan J; Zheng W; Portilla L; Hubbs A; Pavan WJ; Heiss J; Vite CH; Walkley SU; Ory DS; Silber SA; Porter FD; Austin CP; McKew JC Curr Top Med Chem; 2014; 14(3):330-9. PubMed ID: 24283970 [TBL] [Abstract][Full Text] [Related]
24. Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients. García-Robles AA; Company-Albir MJ; Megías-Vericat JE; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Alcalá-Vicente C; Galeano I; Casanova B; Poveda JL J Neurol Sci; 2016 Jul; 366():65-67. PubMed ID: 27288778 [No Abstract] [Full Text] [Related]
25. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease. Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436 [TBL] [Abstract][Full Text] [Related]
26. Methyl-β-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK. Dai S; Dulcey AE; Hu X; Wassif CA; Porter FD; Austin CP; Ory DS; Marugan J; Zheng W Autophagy; 2017 Aug; 13(8):1435-1451. PubMed ID: 28613987 [TBL] [Abstract][Full Text] [Related]
27. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy. Yu D; Swaroop M; Wang M; Baxa U; Yang R; Yan Y; Coksaygan T; DeTolla L; Marugan JJ; Austin CP; McKew JC; Gong DW; Zheng W J Biomol Screen; 2014 Sep; 19(8):1164-73. PubMed ID: 24907126 [TBL] [Abstract][Full Text] [Related]
28. Early experience with compassionate use of 2 hydroxypropyl-beta-cyclodextrin for Niemann-Pick type C disease: review of initial published cases. Megías-Vericat JE; García-Robles A; Company-Albir MJ; Fernández-Megía MJ; Pérez-Miralles FC; López-Briz E; Casanova B; Poveda JL Neurol Sci; 2017 May; 38(5):727-743. PubMed ID: 28155026 [TBL] [Abstract][Full Text] [Related]
29. Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1. Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Navid F; Wassif CA; Cawley NX; Porter FD Mol Genet Metab; 2021 Dec; 134(4):330-336. PubMed ID: 34802899 [TBL] [Abstract][Full Text] [Related]
31. Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1. Yergey AL; Blank PS; Cologna SM; Backlund PS; Porter FD; Darling AJ PLoS One; 2017; 12(4):e0175478. PubMed ID: 28414792 [TBL] [Abstract][Full Text] [Related]
32. Effects of cyclodextrin in two patients with Niemann-Pick Type C disease. Matsuo M; Togawa M; Hirabaru K; Mochinaga S; Narita A; Adachi M; Egashira M; Irie T; Ohno K Mol Genet Metab; 2013 Jan; 108(1):76-81. PubMed ID: 23218948 [TBL] [Abstract][Full Text] [Related]
33. Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin. Cougnoux A; Clifford S; Salman A; Ng SL; Bertin J; Porter FD Mol Genet Metab; 2018 Dec; 125(4):345-350. PubMed ID: 30392741 [TBL] [Abstract][Full Text] [Related]
34. Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C. Puglisi A; Yagci Y Macromol Rapid Commun; 2019 Jan; 40(1):e1800557. PubMed ID: 30216584 [TBL] [Abstract][Full Text] [Related]
35. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin. Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457 [TBL] [Abstract][Full Text] [Related]
36. Synthesis of the Anionic Hydroxypropyl-β-cyclodextrin:Poly(decamethylenephosphate) Polyrotaxane and Evaluation of its Cholesterol Efflux Potential in Niemann-Pick C1 Cells. Egele K; Samaddar S; Schneider N; Thompson D; Wenz G J Mater Chem B; 2019 Jan; 7(4):528-537. PubMed ID: 31372225 [TBL] [Abstract][Full Text] [Related]
37. [Inclusion Solves Insolubility -Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C]. Irie T Yakugaku Zasshi; 2022; 142(4):389-400. PubMed ID: 35370195 [TBL] [Abstract][Full Text] [Related]
38. Analytical Characterization of Methyl-β-Cyclodextrin for Pharmacological Activity to Reduce Lysosomal Cholesterol Accumulation in Niemann-Pick Disease Type C1 Cells. Li R; Hao J; Fujiwara H; Xu M; Yang S; Dai S; Long Y; Swaroop M; Li C; Vu M; Marugan JJ; Ory DS; Zheng W Assay Drug Dev Technol; 2017; 15(4):154-166. PubMed ID: 28631941 [TBL] [Abstract][Full Text] [Related]